Gapping up
In reaction to earnings/guidance:
- MOMO +12.4%, HCP +6.7%, GMS +5.4%, BZFD +4.8%, OXM +4.2%, NAPA +3.6% (also CFO to retire), KMI +0.5%
Other news:
- RXDX +12.2% ($250 mln stock offering)
- RAPT +4.8% (presents update from its phase 1/2 clinical trial for FLX475 as monotherapy and in combination with pembrolizumab in patients with advanced cancer)
- CARG +4.4% (announces $250 mln repurchase program)
- AKRO +4.3% (announces that efruxifermin has received a Breakthrough Therapy Designation from the FDA for the treatment of nonalcoholic steatohepatitis)
- MT +3.2% (inaugurates flagship carbon capture and utilisation project at its steel plant in Ghent Belgium)
- SFM +3.2% (announced that Alisa Gmelich has joined as Senior Vice President Chief Marketing Officer effective December 5)
- PBYI +2.4% (Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium)
- HHC +1.6% (Pershing Square disclosed the purchase of ~657K shares)
- XOM +1.5% (provides corporate plan update; expects to double earnings and cash flow potential by 2027)
- PDCE +1.3% (declares special dividend of $0.65/sh)
- GTHX +1.3% (reports Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment)
- CRTO +1.3% (announces the extension of its share repurchase authorization from $280-480 mln)
- JWN +1.2% (names interim CFO)
- CVX +1.2% (announces 2023 CapEx budgets)
Analyst comments:
- AIRC +2.1% (upgraded to Buy from Sell at Goldman)
- BA +0.7% (assumed with a Buy at Citigroup)